APSR2026-803

Yes
Late-Breaking
Submitted
Oral Presentation
AO04-004
 
 
https://storage.unitedwebnetwork.com/files/1285/1221195-46903-APSR26_MURILLO_HVNIvsNIV_SRMA_Final_440431.pptx
Format: PPTX Only
 
Format: PDF Only
11. Critical Care Medicine
2

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Karl Jeffrey Murillo * Philippine General Hospital Division of Pulmonary Medicine, Department of Medicine Manila Philippines
Mithi Kalayaan Zamora - Philippine General Hospital Division of Pulmonary Medicine, Department of Medicine Manila Philippines
 
 
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Karl Jeffrey
Murillo
karljeffrey.murillo@gmail.com
+639173087667
31-40
Philippines
Original Research
High-Velocity Nasal Insufflation Versus Non-Invasive Ventilation in Acute Hypercapnic Respiratory Failure: A Systematic Review and Meta-Analysis
Maximum 25 words
Abstract Content
High-velocity nasal insufflation (HVNI) is increasingly used as an alternative to non-invasive ventilation (NIV) in patients with acute respiratory failure, including hypercapnic states. However, comparative evidence on clinical outcomes remains limited. This study aimed to evaluate the effectiveness and safety of HVNI compared with NIV in adult patients with acute respiratory failure.
A systematic review and meta-analysis were conducted following PRISMA guidelines. MEDLINE, Cochrane CENTRAL, and ClinicalTrials.gov were searched from inception to January 2026 for randomized controlled trials comparing HVNI with NIV in adults with acute respiratory failure. Primary outcomes were treatment failure and endotracheal intubation. Secondary outcomes included mortality, gas exchange parameters, and patient comfort. Random-effects meta-analysis was performed using Review Manager. Risk of bias was assessed using the Cochrane RoB 2 tool, and certainty of evidence was evaluated using GRADE.
Four randomized controlled trials involving 473 patients were included. HVNI demonstrated comparable efficacy to NIV in treatment failure (RR 0.91, 95% CI 0.67–1.23) and endotracheal intubation (RR 0.95, 95% CI 0.68–1.31). Mortality outcomes were limited but showed no significant difference between groups. HVNI showed similar early improvements in PaCO₂ and pH compared to NIV. Hospital length of stay and duration of respiratory support were modestly shorter with HVNI, although heterogeneity was observed. Patient comfort and tolerance consistently favored HVNI, although these outcomes were qualitative and of very low certainty.
HVNI provides clinical outcomes comparable to NIV in acute respiratory failure. It may offer advantages in patient comfort and tolerability, particularly in patients unable to tolerate mask-based ventilation and in resource-limited settings. Further high-quality studies are needed to better define its role in clinical practice.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Hypercapnic respiratory failure, Noninvasive ventilation, High flow nasal oxygen
maximum 3 keywords and no abbreviations, separated by commas
The authors declare no conflicts of interest. No external funding was received for this study.
275